Micro-Accelerator Radiopharmaceutical Production System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cyclotrons for radiopharmaceutical production are large, power-intensive, and costly, limiting their use in medical facilities due to size, weight, and high power requirements, and they have inefficiencies in processing short-lived radiopharmaceuticals with low yields and long processing times.
Innovation Solution
A compact, low-power biomarker generator system using a micro-accelerator and micro-synthesis system with microreactors or microfluidic chips, optimized for producing small quantities of radioisotopes and radiopharmaceuticals, and an automated quality control system for rapid testing, reducing infrastructure and energy needs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cyclotrons are used for radiopharmaceutical production, then sufficient radioisotope quantity can be produced, but the system requires large size, high power consumption, and substantial infrastructure
Solution Approach 1:
The system divides radioisotope production into two segments: a centralized high-capacity cyclotron for bulk production and a distributed micro-accelerator system for local production. The micro-accelerator produces smaller quantities of radioisotopes (e.g., 1-10 mCi) suitable for individual hospital needs, eliminating the requirement for large conventional cyclotrons while maintaining adequate supply for clinical use.
Solution Approach 2:
The invention transitions from a single large-scale production model to a multi-scale distributed production model. By introducing micro-accelerators at the hospital level, the system creates a hierarchical production structure where bulk production and local production coexist, fundamentally changing the dimensional scale of radioisotope generation from facility-level to point-of-care level.
2Quantity of substance
If conventional cyclotrons are used for radiopharmaceutical production, then sufficient radioisotope quantity can be produced, but the system requires large physical footprint and heavy weight
Solution Approach 1:
The system segments the production function between a centralized facility using conventional cyclotrons and distributed hospital sites using micro-accelerators. The micro-accelerator weighs only approximately 300 pounds (compared to tens of thousands of pounds for conventional cyclotrons), enabling installation in standard hospital rooms without requiring dedicated shielded vaults or special structural support.
Solution Approach 2:
Instead of each hospital installing a full-scale conventional cyclotron, the invention deploys scaled-down copies (micro-accelerators) that replicate the essential function of isotope production. These micro-copies maintain the core acceleration and production capabilities while reducing size and weight by several orders of magnitude.
3Quantity of substance
If conventional radiochemical synthesis systems are used, then sufficient radiopharmaceutical quantity can be produced, but processing time is long and yield is limited
Solution Approach 1:
The microfluidic synthesis system fundamentally changes the physical parameters of the reaction environment by transitioning from milliliter-scale to microliter-scale reaction volumes. This parameter change increases the surface-area-to-volume ratio, enhancing heat transfer and mass transport rates. The system achieves processing times of minutes instead of hours, with yield fractions exceeding 90% compared to 50-60% in conventional systems.
Solution Approach 2:
The invention replaces conventional mechanical stirring and bulk-phase reaction mechanisms with microfluidic flow-based mixing and interfacial reaction mechanisms. The microfluidic system uses laminar flow patterns and diffusion-driven mixing at micro-scales, eliminating the need for mechanical stirrers and enabling precise control of reaction conditions, which dramatically reduces processing time and increases efficiency.
4Quantity of substance
If conventional radiochemical synthesis systems are used, then sufficient radiopharmaceutical quantity can be produced, but the system is complex and requires substantial infrastructure
Solution Approach 1:
The microfluidic synthesis system merges multiple separate operations (mixing, reaction, purification, and formulation) into a single integrated chip-based platform. All synthesis steps occur within the microfluidic device, eliminating the need for separate reactors, filtration systems, and purification equipment that characterize conventional systems. This consolidation dramatically reduces device complexity while maintaining production capability.
Solution Approach 2:
The invention applies local quality control by performing quality assurance measurements directly at the point of synthesis using the microfluidic platform. The system incorporates on-chip sensors and detectors that monitor reaction progress, product formation, and purity in real-time, eliminating the need for complex off-line analytical equipment and simplifying the overall system architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient, on-demand production of radiopharmaceuticals with reduced size, weight, and power consumption, allowing for in-house generation even in small hospitals, and significantly shortens processing times and improves yields, while ensuring quality control is conducted quickly and efficiently.
Implementation Method 1
Cyclotrons are used to generate high energy charged particle beams for purposes such as nuclear physics research and medical treatments
Implementation Method 2
A compact, low-power biomarker generator system using a micro-accelerator and micro-synthesis system with microreactors or microfluidic chips, optimized for producing small quantities of radioisotopes and radiopharmaceuticals
Implementation Method 3
The large linear dimensions of the reaction vessel in radiochemical synthesis systems commonly used in biomarker generators result in a small ratio of surface area-to-volume and effectively limit the heat transfer and mass transport rates
Implementation Method 4
an automated quality control system for rapid testing, reducing infrastructure and energy needs
Data Source
AI summary
An automated radiopharmaceutical production and quality control system includes a particle accelerator, a radiopharmaceutical micro-synthesis subsystem, and quality control subsystem. The micro-accelerator of the improved biomarker generator is optimized for producing radioisotopes useful in synthesizing radiopharmaceuticals in quantities on the order of multiple unit doses, allowing for significant reductions in size, power requirements, and weight when compared to conventional radiopharmaceutical cyclotrons. The radiopharmaceutical micro-synthesis subsystem encompasses a small volume chemical synthesis system comprising a microreactor and/or a microfluidic chip and optimized for synthesizing the radiopharmaceutical in small quantities, allowing for significant reductions in processing time and in the quantity of radioisotope required. The automated quality control subsystem is used to test the composition and characteristics of the radiopharmaceutical to ensure that it is safe to inject.